Table 2.

The inhibitory activity (IC₅₀ uM) of compounds (7 (a, b), 9–42) and selectivity-fold against HCT-116, SD never exceeded 5%, (n = 9), and treatment for 48 h

Compound	IC50 uM		Selectivity Fold	Compound	IC50 uM		Selectivity Fold
	HCT-116	CaCo-2			HCT-116	CaCo-2
7a	74.98	913.8	12	26	139.3	469.3	3.4
7b	101.0	178.7	1.8	27	332.2	479.0	1.4
9	60.39	95.3	1.6	28	119.7	205.1	1.7
10	23.41	58.08	2.5	29	11.9	76.0	6
11	30.82	69.94	2.3	30	15.6	47.5	3
12	83.22	128.77	1.6	31	51.6	59.8	1
13	27.14	77.18	2.8	32	170.6	NOT ACTIVE	-
14	56.99	116.7	2.0	33	38.7	67.3	1.7
15	101.1	171.0	1.7	34	121.5	200
16	28.43	70.52	2.5	35	37.8	32.9	0.9
17	127.5	194.4	1.5	36	76.86	504	6.6
18	207.7	652.4	3.0	37	447.1	756	1.7
19	39.08	94.12	2.4	38	476.7	NOT ACTIVE	-
20	22.95	84.01	3.7	39	2304	NOT ACTIVE	-
21	43.68	235.77	5.4	40	65.4	61.9	0.9
22	37.42	98.26	2.6	41	167.1	325.6	1.9
23	39.11	60.57	1.5	42	181	346	1.9
24	51.39	199.26	3.9	LY294002	7.4
25	229.8	385.7	1.7